Bank of America’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-83,041
| Closed | -$1.09M | – | 5779 |
|
|
2025
Q4 | $1.09M | Buy |
83,041
+33,840
| +69% | +$404K | ﹤0.01% | 4478 |
|
|
2025
Q3 | $358K | Sell |
49,201
-427
| -0.9% | -$2.89K | ﹤0.01% | 5981 |
|
|
2025
Q2 | $266K | Buy |
49,628
+3,881
| +8% | +$18.8K | ﹤0.01% | 6051 |
|
|
2025
Q1 | $244K | Sell |
45,747
-46,031
| -50% | -$322K | ﹤0.01% | 6068 |
|
|
2024
Q4 | $820K | Buy |
91,778
+10,136
| +12% | +$108K | ﹤0.01% | 5195 |
|
|
2024
Q3 | $899K | Sell |
81,642
-48,301
| -37% | -$537K | ﹤0.01% | 5117 |
|
|
2024
Q2 | $1.18M | Buy |
129,943
+20,543
| +19% | +$201K | ﹤0.01% | 4799 |
|
|
2024
Q1 | $1.54M | Buy |
109,400
+54,436
| +99% | +$678K | ﹤0.01% | 4632 |
|
|
2023
Q4 | $422K | Buy |
54,964
+21,380
| +64% | +$118K | ﹤0.01% | 5612 |
|
|
2023
Q3 | $251K | Buy |
33,584
+13,094
| +64% | +$112K | ﹤0.01% | 5762 |
|
|
2023
Q2 | $171K | Buy |
20,490
+7,328
| +56% | +$84.6K | ﹤0.01% | 5943 |
|
|
2023
Q1 | $175K | Buy |
13,162
+2,050
| +18% | +$27.7K | ﹤0.01% | 5994 |
|
|
2022
Q4 | $165K | Buy |
11,112
+3,020
| +37% | +$31.1K | ﹤0.01% | 6011 |
|
|
2022
Q3 | $73K | Buy |
8,092
+7,527
| +1,332% | +$50.5K | ﹤0.01% | 6501 |
|
|
2022
Q2 | $2K | Buy |
565
+550
| +3,667% | +$2.47K | ﹤0.01% | 7760 |
|
|
2022
Q1 | $0 | Sell |
15
-3,892
| -100% | -$23.2K | ﹤0.01% | 8244 |
|
|
2021
Q4 | $21K | Buy |
3,907
+2,630
| +206% | +$17.3K | ﹤0.01% | 7499 |
|
|
2021
Q3 | $11K | Buy |
1,277
+1,046
| +453% | +$10K | ﹤0.01% | 7541 |
|
|
2021
Q2 | $3K | Sell |
231
-5,401
| -96% | -$70.1K | ﹤0.01% | 7491 |
|
|
2021
Q1 | $98K | Buy |
5,632
+3,259
| +137% | +$58.9K | ﹤0.01% | 6396 |
|
|
2020
Q4 | $31K | Buy |
2,373
+829
| +54% | +$14.8K | ﹤0.01% | 6476 |
|
|
2020
Q3 | $57K | Sell |
1,544
-2,569
| -62% | -$102K | ﹤0.01% | 5960 |
|
|
2020
Q2 | $158K | Buy |
+4,113
| New | +$146K | ﹤0.01% | 5402 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6829 |
|
|
2019
Q4 | – | Sell |
-71
| Closed | -$2K | – | 7068 |
|
|
2019
Q3 | $2K | Sell |
71
-12
| -14% | -$475 | ﹤0.01% | 6980 |
|
|
2019
Q2 | $4K | Hold |
83
| – | – | ﹤0.01% | 6862 |
|
|
2019
Q1 | $4K | Hold |
83
| – | – | ﹤0.01% | 6818 |
|
|
2018
Q4 | $2K | Hold |
83
| – | – | ﹤0.01% | 6889 |
|
|
2018
Q3 | $4K | Hold |
83
| – | – | ﹤0.01% | 6862 |
|
|
2018
Q2 | $5K | Hold |
83
| – | – | ﹤0.01% | 6791 |
|
|
2018
Q1 | $9K | Buy |
+83
| New | +$8.3K | ﹤0.01% | 6624 |
|
|
2017
Q4 | – | Sell |
-125
| Closed | -$16K | – | 7019 |
|
|
2017
Q3 | $16K | Buy |
+125
| New | +$10.4K | ﹤0.01% | 6357 |
|
|
2017
Q2 | – | Sell |
-17
| Closed | -$2K | – | 6923 |
|
|
2017
Q1 | $2K | Buy |
+17
| New | +$2.34K | ﹤0.01% | 6782 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | – | – | 7024 |
|
|
2016
Q3 | $0 | Sell |
1
-24
| -96% | -$6.32K | ﹤0.01% | 7095 |
|
|
2016
Q2 | $6K | Buy |
+25
| New | +$7.54K | ﹤0.01% | 6616 |
|
|
2016
Q1 | – | Sell |
-2
| Closed | -$1K | – | 6987 |
|
|
2015
Q4 | $1K | Sell |
2
-10
| -83% | -$4.8K | ﹤0.01% | 7178 |
|
|
2015
Q3 | $6K | Buy |
+12
| New | +$8.57K | ﹤0.01% | 6703 |
|
Bank of America's ATXS Position: Q1 2026 in Review
Bank of America sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 83,041 shares — an estimated $1.09M sold.
Bank of America first reported a position in ATXS in Q3 2015 and held it in 36 quarters. The position peaked at $1.54M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Bank of America reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 83,041 Astria Therapeutics shares in Q1 2026, an estimated $1.09M.
- Bank of America first reported a position in Astria Therapeutics in Q3 2015 and held it in 36 quarters.
- Bank of America's Astria Therapeutics position peaked at $1.54M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.